Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split to Boost Share Price
Summary
Bluejay Diagnostics, Inc. has completed a 1-for-4 reverse stock split, effective January 29, 2026, significantly reducing its outstanding shares and aiming to increase its per-share price.
Key Events
-
Reverse Stock Split Implemented
The company completed a 1-for-4 reverse stock split, effective January 29, 2026, converting every four existing shares into one new share.
-
Share Structure Adjustment
Outstanding common stock decreased from approximately 2.83 million to 708,533 shares, with proportionate adjustments to prefunded warrants and equity awards.
-
Nasdaq Listing Compliance
The reverse split is typically undertaken to increase the per-share price, often to meet minimum bid price requirements for continued listing on the Nasdaq Capital Market.
Analysis
This 8-K filing confirms the completion of Bluejay Diagnostics' 1-for-4 reverse stock split, a significant corporate action for a micro-cap company. While mechanically neutral in terms of ownership percentage, reverse splits are generally viewed negatively by the market as they often signal underlying financial distress or a struggle to maintain exchange listing requirements. For Bluejay Diagnostics, with its very small market capitalization, this move is critical for potentially regaining compliance with Nasdaq's minimum bid price rule, thereby avoiding delisting. Investors should monitor the stock's performance post-split and any subsequent announcements regarding listing compliance.
At the time of this filing, BJDX was trading at $3.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.51 to $40.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.